We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Sensus Healthcare, Inc. (SRTS) Outpaced the Stock Market Today
Read MoreHide Full Article
In the latest close session, Sensus Healthcare, Inc. (SRTS - Free Report) was up +2.54% at $4.44. The stock's change was more than the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw an increase of 0.74%.
Prior to today's trading, shares of the company had lost 8.65% lagged the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.
The investment community will be closely monitoring the performance of Sensus Healthcare, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of $0.01, indicating a 90% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.8 million, down 4.76% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.11 per share and a revenue of $41.95 million, indicating changes of -73.17% and +0.34%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #4 (Sell).
Investors should also note Sensus Healthcare, Inc.'s current valuation metrics, including its Forward P/E ratio of 39.36. This indicates a premium in contrast to its industry's Forward P/E of 22.47.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Sensus Healthcare, Inc. (SRTS) Outpaced the Stock Market Today
In the latest close session, Sensus Healthcare, Inc. (SRTS - Free Report) was up +2.54% at $4.44. The stock's change was more than the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw an increase of 0.74%.
Prior to today's trading, shares of the company had lost 8.65% lagged the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.
The investment community will be closely monitoring the performance of Sensus Healthcare, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of $0.01, indicating a 90% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.8 million, down 4.76% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.11 per share and a revenue of $41.95 million, indicating changes of -73.17% and +0.34%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #4 (Sell).
Investors should also note Sensus Healthcare, Inc.'s current valuation metrics, including its Forward P/E ratio of 39.36. This indicates a premium in contrast to its industry's Forward P/E of 22.47.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.